We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · November 22, 2021

Impacts of Completion Lymph Node Dissection and Adjuvant Therapies in Japanese Stage III Melanoma Patients

International Journal of Clinical Oncology

 

Additional Info

International Journal of Clinical Oncology
Impact of the changes in the completion lymph node dissection criteria and approval of adjuvant therapies on the real-world outcomes of Japanese stage III melanoma patients
Int. J. Clin. Oncol. 2021 Dec 01;26(12)2338-2346, D Ogata, K Tanese, Y Nakamura, M Otsuka, K Namikawa, T Funakoshi, S Yoshikawa, K Tsutsui, K Nakama, S Jinnai, Y Kiyohara, A Takahashi, N Yamazaki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading